Literature DB >> 21801193

The development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). Part I: construction and psychometric properties.

Monika Milian1, Philipp Teufel, Juergen Honegger, Baptist Gallwitz, Guenter Schnauder, Tsambika Psaras.   

Abstract

OBJECTIVE: To develop a disease-specific questionnaire for Cushing's disease (CD), the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25).
METHODS: Sources for item generation consisted of technical literature, interviews with patients and the rating of neurosurgeons, endocrinologists and a neuropsychologist. A preliminary inventory with 64 items was handed out to 63 CD patients. Twenty-eight patients filled out the questionnaire preoperative, the remaining 35 patients evaluated their health-related quality of life (HRQoL) retrospectively. Item reduction and scale generation followed the principles of classical test theory. Validation was performed with the WHOQoL-BREF.
RESULTS: The final version of the Tuebingen CD-25 contained 25 items, showed high reliability (Cronbach's alpha = 0.93) and validity (r = -0.65) and includes the subdomains Depression, Sexual Activity, Environment, Eating Behaviour, Bodily Restrictions and Cognition. The retrospective rating of the Tuebingen CD-25 showed similar results compared to the pretreatment group. We found a non-linear correlation between the Tuebingen CD-25 scores and patients' age, younger (21-30 years) and middle-aged (51-60 years) patients having inferior HRQoL than patients between 31 and 50 years and older than 61 years. Preoperative 24 h urinary free cortisol (UFC) levels correlated significantly with the subscale Cognition and only marginally failed significance level for the subscale Eating Behaviour, while preoperative cortisol and ACTH levels did not correlate with any scale.
CONCLUSION: The Tuebingen CD-25 is a valid and reliable instrument to evaluate HRQoL in CD. Based on impairment of HRQoL for the different subdimensions, specific support can be offered to the patients.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 21801193     DOI: 10.1111/j.1365-2265.2011.04191.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL.

Authors:  Cornelie D Andela; Nicolasine D Niemeijer; Margreet Scharloo; Jitske Tiemensma; Shaaji Kanagasabapathy; Alberto M Pereira; Noëlle G A Kamminga; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Coping strategies have a strong impact on quality of life, depression, and embitterment in patients with Cushing's disease.

Authors:  Sonja Siegel; Monika Milian; Bernadette Kleist; Tsambika Psaras; Maria Tsiogka; Dagmar Führer; Maria Koltowska-Häggström; Jürgen Honegger; Oliver Müller; Ulrich Sure; Christa Menzel; Michael Buchfelder; Ilonka Kreitschmann-Andermahr
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

Review 4.  Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies.

Authors:  Cornelie D Andela; Margreet Scharloo; Alberto M Pereira; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

Review 5.  Cushing's Disease - Quality of Life, Recurrence and Long-term Morbidity.

Authors:  Isabel Huguet; Georgia Ntali; Ashley Grossman; Niki Karavitaki
Journal:  Eur Endocrinol       Date:  2015-04-11

Review 6.  Quality of life and other outcomes in children treated for Cushing syndrome.

Authors:  Margaret F Keil
Journal:  J Clin Endocrinol Metab       Date:  2013-05-02       Impact factor: 5.958

7.  Loss of Efficacy of Pasireotide After its Re-Administration: is There a Reason Why?

Authors:  Stylianos Mandanas; Lemonia Mathiopoulou; Maria Boudina; Alexandra Chrisoulidou; Kalliopi Pazaitou-Panayiotou
Journal:  Rare Tumors       Date:  2016-12-23

8.  Illustration of patient-reported outcome challenges and solutions in rare diseases: a systematic review in Cushing's syndrome.

Authors:  Naomi Knoble; Gabrielle Nayroles; Cherry Cheng; Benoit Arnould
Journal:  Orphanet J Rare Dis       Date:  2018-12-19       Impact factor: 4.123

Review 9.  Disease-specific quality of life evaluation and its determinants in Cushing's syndrome: what have we learnt?

Authors:  X Badia; E Valassi; M Roset; S M Webb
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

10.  The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary.

Authors:  Cornelie D Andela; Margreet Scharloo; Steven Ramondt; Jitske Tiemensma; Olga Husson; Sofia Llahana; Alberto M Pereira; Ad A Kaptein; Noëlle G A Kamminga; Nienke R Biermasz
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.